الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
Hepatitis B virus (HBV) infection is considered a major public health problem worldwide, that increases the risk of more than 250 million people to developing terminal liver disease. The predominant route of HBV transmission in highly endemic areas is perinatal transmission, including intrauterine, intrapartum, and puerperal transmissions, Infection with HBV at an early stage of life will lead to chronicity in the majority of cases (>95%). chronic hepatitis B virus (HBV) infection has a wide range of clinical manifestations, from asymptomatic carriers to severe chronic liver disease, including cirrhosis and hepatocellular carcinoma (HCC). liver cirrhosis is a major risk factor for development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus infection. Aim of the work:to characterize patients with chronic hepatitis B virus infection who achieving HBsAg loss during nucleos(t)ide analogue therapy.to detect predictors for surface antigen loss on those patients.ubjects and methods: This study was performed after Ethical approval for the study by the Scientific Council of Internal Medicine Department, Egypt Board for Medical Specification and obtaining adequate consent. The present etrospective study was carried out on 434 patients with chronic HBV infection attending the outpatient clinic of Egyptian Liver Research Institute and Hospital (ELRIAH) during the period from March 2016 to March 2022.All patients were; designated according to the inclusion and exclusion criteria. Results : This retrospective cohort study was conducted on 434 chronic HBV mono-infected patients. For these chronic naïve HBV patients HBSAg quantification was assessed before treatment and 48weeks after start of treatment according to EASL guidelines for treatment.As regard to HBV treatment, in 125 patients on Lamivudine, 174 patients on Entecavir, 135 patients on Tenofovir.In our study, 115 out of 125 patients on lamivudine therapy were with virological response, no patients were with seroclearance and 10 cases with breathrough. In entecavir group, 155 out of 174 patients were with virological response, 16 patients were with seroclearance and 3 cases with breakthrough. In tenofovir group, 123 out of 135 patients were with virological response and 12 patients were with seroclearance. Statistically, there were significant differences between the three studied groups regarding seroclearance and breakthough (p < 0.05) and a non-significant difference regarding virological response (p > 0.05).Conclusion: The combined use of HBsAg and HBV DNA assessment in patients with CHB therapy can guide the clinician to evaluate the chances of treatment response with the possibility to individualize therapy strategies, such as “continue and follow-up”, “add-on, switch or stop and follow-up”.Low baseline DNA level and HBsAg level is a good predictor for responders and cure.